Opinion

Video

Sequencing Considerations in Relapsed/Refractory CLL

Author(s):

Callie Coombs, MD ,Matthew Davids, MD, MMSc

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.

Video content above is prompted by the following:

  • What sequencing considerations influence your choice of upfront therapy for chronic lymphocytic leukemia (CLL), and how do these decisions shape the selection of treatments in the relapsed/refractoryCLL setting?
  • How does the treatment sequencing study in CLL/SLL by Rhodes and colleagues, presented at the 2024 American Society of Hematology annual meeting, influence your clinical approach?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Hans Lee
Dr María Díez Campelo
4 experts in this video
4 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
DLBCL | Image: Atlas of Haematological Cytology
July 16th 2025

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

Mary Caffrey
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Rise in drug pricing | Image Credit: Alex Puhovoy - stock.adobe.com
July 14th 2025

Medicare Inflation Rebates Show Limited Impact on Drug Price Trends

Brooke McCormick
Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Lung cancer | Image credit: appledesign - stock.adobe.com
July 14th 2025

HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

Julia Bonavitacola
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).
3D illustration showing abundant lymphoblasts in blood | Image credit: Dr_Microbe - stock.adobe.com
July 14th 2025

Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL

Caroline Seymour
Obecabtagene autoleucel showed over 70% response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), demonstrating efficacy across all age groups in recent trials.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo